In a surprise move that drove its stock up by 292% in early trading, Chimerix Inc. revealed plans for a U.S. NDA filing by year-end, seeking accelerated approval of dordaviprone (ONC-201) to treat recurrent H3 K27M-mutant diffuse glioma, a highly aggressive tumor with limited treatment options.

Wigen Biomedicine Technology (Shanghai) Co. Ltd. has divulged compounds acting as histone deacetylase 1 (HDAC1) and/or 2 (HDAC2) inhibitors reported to be useful for the treatment of cancer.

Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has synthesized antibody-drug conjugates.

Glioblastoma survival has not improved in the last 30 years and there is an urgent need to develop novel therapeutic approaches for it.

Researchers have disclosed compounds reported to be useful for the treatment of cancer and more.

Researchers from Excellamol Inc. presented the design and preclinical characterization of XM161-SN38, a novel IL-13Rα2-targeting polypeptide-drug conjugate being evaluated for the treatment of gliomas.

Researchers from the Children's Hospital of Philadelphia presented data from a study that aimed to identify novel biologically relevant cell surface immunotherapeutic targets for neuroblastoma.